AR121809A2 - PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS - Google Patents
PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODSInfo
- Publication number
- AR121809A2 AR121809A2 ARP210100945A ARP210100945A AR121809A2 AR 121809 A2 AR121809 A2 AR 121809A2 AR P210100945 A ARP210100945 A AR P210100945A AR P210100945 A ARP210100945 A AR P210100945A AR 121809 A2 AR121809 A2 AR 121809A2
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- lymphocyte
- peptide
- antibody
- kit
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con péptidos, proteínas, ácidos nucleicos y células para su uso en métodos inmunoterapéuticos. En particular, la presente invención se relaciona con inmunoterapia para el cáncer. La presente invención se relaciona además con epitopes de péptidos de células T asociados con tumores, solos o en combinación con otros péptidos asociados con tumores que pueden, por ejemplo, servir como ingredientes farmacéuticos activos de composiciones para vacunas que estimulan la respuesta inmune como ingredientes farmacéuticos activos de composiciones para vacunas que estimulan la repuesta inmune antitumoral o para estimular células T ex vivo y transferirlas a pacientes. Los péptidos unidos a moléculas del complejo de histocompatibilidad principal (MHC) o los péptidos como tales también pueden ser el blando de anticuerpos, receptores de células T solubles y otras moléculas de unión.The present invention relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present invention relates to immunotherapy for cancer. The present invention further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can, for example, serve as active pharmaceutical ingredients of compositions for vaccines that stimulate the immune response as pharmaceutical ingredients. active ingredients of compositions for vaccines that stimulate the antitumor immune response or to stimulate T cells ex vivo and transfer them to patients. Peptides bound to major histocompatibility complex (MHC) molecules or peptides as such may also be the target of antibodies, soluble T cell receptors and other binding molecules.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562139189P | 2015-03-27 | 2015-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121809A2 true AR121809A2 (en) | 2022-07-13 |
Family
ID=59256464
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100818A AR104113A1 (en) | 2015-03-27 | 2016-03-28 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
ARP180102260A AR112781A2 (en) | 2015-03-27 | 2018-08-08 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
ARP210100947A AR121810A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
ARP210100945A AR121809A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100818A AR104113A1 (en) | 2015-03-27 | 2016-03-28 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
ARP180102260A AR112781A2 (en) | 2015-03-27 | 2018-08-08 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
ARP210100947A AR121810A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Country Status (1)
Country | Link |
---|---|
AR (7) | AR104113A1 (en) |
-
2016
- 2016-03-28 AR ARP160100818A patent/AR104113A1/en unknown
-
2018
- 2018-08-08 AR ARP180102260A patent/AR112781A2/en unknown
-
2021
- 2021-04-09 AR ARP210100948A patent/AR121811A2/en unknown
- 2021-04-09 AR ARP210100947A patent/AR121810A2/en unknown
- 2021-04-09 AR ARP210100949A patent/AR121812A2/en unknown
- 2021-04-09 AR ARP210100945A patent/AR121809A2/en unknown
- 2021-09-13 AR ARP210102531A patent/AR123493A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR121811A2 (en) | 2022-07-13 |
AR121810A2 (en) | 2022-07-13 |
AR121812A2 (en) | 2022-07-13 |
AR112781A2 (en) | 2019-12-11 |
AR104113A1 (en) | 2017-06-28 |
AR123493A2 (en) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR127117A2 (en) | NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | |
CL2020000987A1 (en) | New peptide from seq id no: 89 for use in immunotherapy against lung cancer, including small cell lung cancer and other cancers (divisional application no. 201701819) | |
CL2021002525A1 (en) | Immunotherapeutic peptides for use in cancer immunotherapy (divisional of application no. 201801531) | |
CL2023001346A1 (en) | Use of peptides in immunotherapy against small cell lung cancer and others. | |
CL2020001985A1 (en) | Peptides and peptide combinations for use in immunotherapy against chronic lymphocytic leukemia (LLC) and other cancers. (divisional request 201801532) | |
CL2018000780A1 (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other types of cancer | |
CO2018000252A2 (en) | Peptides and combinations of peptides for immunotherapy against epithelial ovarian cancer and other types of cancer | |
CR20180398A (en) | PEPTIDES, COMBINATIONS OF PEPTIDES AND CELLS FOR USE IN IMMUNOTHERAPY AGAINST BLADDER CANCER AND OTHER TYPES OF CANCER | |
CR20180001A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER. | |
CR20180245A (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TYPES OF CANCER | |
CO2017012891A2 (en) | Peptides and combinations of peptides for immunotherapy against ovarian cancer and other types of cancer | |
CR20180051A (en) | NEW CELLULAR EPITHOPES AND NEW COMBINATIONS OF CELLULAR EPITHOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER TYPES OF CANCER. | |
CO2019008008A2 (en) | New peptides and new peptide combinations for use in immunotherapy against ovarian and other cancers | |
CR20180040A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS TO CREATE SUPPORTS FOR USE AGAINST CANCER OF PANCREAS AND OTHER TYPES OF CANCER. | |
AR121024A2 (en) | PEPTIDE, ENCODING NUCLEIC ACID, ANTIBODY, T-LYMPHOCYTE, T-LYMPHOCYTE RECEPTOR, APTAMER, RECOMBINANT HOST CELL, PHARMACEUTICAL COMPOSITION AND EQUIPMENT | |
CR20220115A (en) | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (Div. 2017-522) | |
CO2019012077A2 (en) | Peptides and combinations thereof for use in immunotherapy against various types of cancer | |
CL2021000177A1 (en) | Peptides, peptide combinations, cells and kits for use in cancer immunotherapy (divisional application no. 201802360) | |
CL2020002935A1 (en) | Peptides for use in cancer immunotherapy | |
CL2021001011A1 (en) | Peptides and peptide combinations for use in immunotherapy against small cell lung cancer and other types of cancer (divisional application no. 201800780) | |
CL2017002346A1 (en) | New peptides and new combination of peptides for use in immunotherapy against pancreatic cancer and other types of cancer | |
CO2018000247A2 (en) | New cell epitopes and new combinations of cell epitopes for use in the immunotherapy of myeloma and other types of cancer | |
CO2017010830A2 (en) | Peptides and combinations of peptides and supports | |
AR121810A2 (en) | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS | |
CR20170522A (en) | PEPTIDES AND COMBINATION OF NOVELED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |